Previous close | 45.1750 |
Open | 45.1800 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 45.1800 - 45.1800 |
52-week range | 45.1800 - 45.1800 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.6340 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today provides an update on its clinical and pre-clinical pipeline, including an update on its lead drug candidate, the novel anti-FcγRIIB antibody BI-1206.
BioInvent International (STO:BINV)
BioInvent International (STO:BINV)